Clinical Evidence: What the Published Trials Really Show
Wegovy v Mounjaro: Understanding the Clinical Trial Landscape
When examining wegovy v mounjaro results, it's crucial to understand that both treatments have been studied in separate clinical programmes with different trial designs and patient populations. Wegovy (semaglutide) was evaluated in the comprehensive STEP clinical trial programme, whilst Mounjaro (tirzepatide) underwent the SURMOUNT trials for weight management. Both prescription-only medicines demonstrated significant weight loss outcomes when used alongside a reduced-calorie diet and increased physical activity. The key distinction lies in their mechanisms: Wegovy targets GLP-1 receptors exclusively, whilst Mounjaro activates both GIP and GLP-1 receptors as a dual agonist.
Understanding these trial differences helps explain why direct percentage comparisons between wegovy v mounjaro can be misleading. Each programme studied different patient populations, used varying trial durations, and employed distinct primary endpoints. What matters most is that both treatments have robust clinical evidence supporting their effectiveness for weight management in appropriate patients. At EverydayMeds, our prescribers can help you understand which treatment aligns best with your individual circumstances and medical history.
Wegovy v Mounjaro Pricing: Transparent UK Costs
The cost comparison for wegovy v mounjaro reveals important considerations for UK patients. Wegovy pricing at EverydayMeds starts with 0.25mg pens at £79.99 (with FIRST40 for new customers), progressing through 0.5mg at £94.99, 1mg at £99.99, 1.7mg at £139.99, to maintenance 2.4mg at £209.99. Our bundle options provide convenient multi-month supplies, such as the Intro Trio (0.25mg, 0.5mg, 1mg) for £299.99, supporting your complete dose escalation journey. Returning customers benefit from code DOSE25 applied at checkout.
When considering wegovy v mounjaro costs, remember that both require similar dose escalation protocols and ongoing prescriber supervision. The investment in either treatment reflects the comprehensive clinical monitoring, cold-chain storage requirements, and advanced pharmaceutical technology involved. Our transparent pricing includes prescriber review, clinical assessment, and next-day temperature-controlled delivery, ensuring you receive authentic medication through our GPhC-registered pharmacy (#9012878). Payment plans and subscription options help manage the ongoing investment in your weight management journey.
STEP Trial Evidence: What Wegovy Clinical Data Shows
The wegovy v mounjaro evidence base begins with Wegovy's landmark STEP trials, particularly STEP 1 published by Wilding et al. in NEJM, 2021. In clinical trials, patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks, compared to 2.4% with placebo. STEP 3 demonstrated that intensive behavioural therapy support enhanced outcomes to approximately 16% average weight loss.
Long-term wegovy v mounjaro considerations include STEP 5 data showing sustained weight loss of approximately 15.2% at 2 years, and the recent SELECT cardiovascular outcomes trial demonstrating 20% reduction in major cardiovascular events. These results represent averages from controlled clinical trials, and individual responses may vary significantly based on adherence, lifestyle factors, and metabolic differences.
How Wegovy Works: GLP-1 Mechanism Explained
Understanding the wegovy v mounjaro mechanism differences helps explain their clinical profiles. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormone (GLP-1). When injected once weekly using the FlexTouch pen, semaglutide binds to GLP-1 receptors in your brain's appetite control centres, reducing hunger signals and promoting satiety after smaller meals. This mechanism may also slow gastric emptying, helping you feel fuller for longer periods. Additionally, GLP-1 receptor activation can reduce food cravings, particularly for high-calorie foods, supporting sustainable dietary changes. The weekly dosing schedule helps maintain consistent hormone levels, unlike rapid-acting appetite suppressants that require multiple daily doses.
EverydayMeds Ordering: Simple 3-Step Process
Accessing wegovy v mounjaro through EverydayMeds begins with our streamlined 3-minute online clinical assessment, covering your medical history, current medications, and weight management goals. Our UK-registered prescribers review your assessment within 3 working days (or 24 hours with express service), ensuring clinical appropriateness before prescribing either treatment. Once approved, your medication ships via next-day delivery using temperature-controlled cold-chain logistics, maintaining the 2-8°C storage requirements throughout transit. Each delivery includes detailed injection guidance, dose escalation schedules, and access to our ongoing clinical support team. This comprehensive approach ensures you receive not just authentic medication, but complete clinical oversight throughout your treatment journey.
Storage and Practical Considerations: Wegovy v Mounjaro
Practical differences in the wegovy v mounjaro comparison include storage flexibility and injection experience. Wegovy pens must be stored in the fridge at 2-8°C before first use, but offer superior travel convenience with 6 weeks room temperature stability (below 30°C) once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit. Both use pre-filled injection pens, though Wegovy's FlexTouch design has been refined through years of diabetes market experience. The dose escalation for Wegovy follows a structured 16-week pathway: 0.25mg (weeks 1-4), 0.5mg (weeks 5-8), 1mg (weeks 9-12), 1.7mg (weeks 13-16), then 2.4mg maintenance. This gradual escalation helps minimise gastrointestinal side effects whilst optimising weight loss outcomes.
UK Clinical Outcomes: Real-World Wegovy v Mounjaro Results
Real-world wegovy v mounjaro outcomes in the UK reflect the controlled trial evidence whilst highlighting individual variation. NHS specialist weight management services report that patients achieving optimal results with Wegovy typically demonstrate strong adherence to the weekly injection schedule and concurrent lifestyle modifications. The NICE TA875 recommendation for Wegovy acknowledges its clinical effectiveness when used within specialist weight management programmes. Success factors include realistic expectation setting, regular clinical monitoring, and integrated dietary counselling.
Long-term wegovy v mounjaro success requires understanding that weight management is a chronic condition requiring ongoing treatment. STEP 1 extension data shows patients regained approximately two-thirds of lost weight within one year of stopping Wegovy, emphasising that sustainable results depend on continued treatment and lifestyle maintenance. Our clinical team provides ongoing support to optimise your treatment experience and maximise long-term success with whichever option proves most suitable.
Making Your Wegovy v Mounjaro Decision
Your wegovy v mounjaro choice should be guided by clinical evidence, individual medical history, and prescriber expertise rather than marketing claims or anecdotal reports. Both treatments are available through EverydayMeds, and our clinical team can help determine which option aligns with your specific circumstances, medical history, and treatment goals. Factors influencing this decision include your BMI, existing medical conditions, medication interactions, and personal preferences regarding injection frequency and side effect profiles. Starting your clinical assessment today with code FIRST40 ensures you receive expert guidance in making this important treatment decision. Our GPhC-registered pharmacy (#9012878) provides both options with complete clinical oversight, next-day delivery, and ongoing support throughout your weight management journey.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
